Abstract
BACKGROUND: The incidence rate of uveitis in secukinumab-treated patients with axial spondyloarthritis (axSpA) was previously reported. OBJECTIVE: To evaluate the incidence rate of uveitis in patients with axSpA and psoriatic arthritis (PsA) treated with secukinumab or placebo during placebo-controlled phase III studies. DESIGN: This was a post hoc analysis from 11 phase III studies. METHODS: Pooled data from axSpA (MEASURE 1-5 and PREVENT studies) and PsA (FUTURE 1-5 studies) were analyzed. RESULTS: In the axSpA cohort (N = 1980), the incidence rate for uveitis was 1.29 per 100 patient-years in the secukinumab 150 mg and 1.72 per 100 patient-years in the placebo arm. In the PsA cohort (N = 2453), the incidence rate for uveitis was 0.71 per 100 patient-years in the secukinumab 300 mg arm; no events were reported in the placebo arm. CONCLUSION: During the placebo-controlled phase, a numerically lower incidence of uveitis was observed in secukinumab-treated axSpA patients. In PsA patients, the incidence was low in secukinumab-treated patients, while uveitis was not reported in the placebo group.